Author Archive

Carnival of Biotechnology

This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, and interesting commentary on issues in commercialization Industry Trends Forbes presents Genentech’s Next Act. his dialogue with Genentech’s chief officers acknowledges the longshot Genentech was in its early days and plots the future paths Genentech […]


Lessons and analogies from other industries

Guest content from John Avellanet, managing director of Cerulean Associates: As professionals affiliated with the biotechnology industry, we often forget that many of the struggles faced today have been solved before by other fields and industries. As Ambrose Bierce wrote, “There is nothing new under the sun, but there are lots of old things we […]


Can Science Be a Business?

Harvard’s Gary Pisano has recently published a book titled “Science Business: The Promise, the Reality, and the Future of Biotech“ in which he assesses the performance of the biotechnology sector and, in finding it lacking, proceeds to recommend a series of suggestions to improve the fundamental architecture of the industry. While I enjoyed the book […]


Carnival of Biotechnology

Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news for Merck, and good and bad news for the biotechnology industry as a whole. News and Trends The Washington Times has an update on the signing of the Animal Enterprise Terrorism Act. Bolstered by recent […]


Carnival of Biotechnology

Intellectual Property and Lawsuits Culture Dish has a post on a DNA sequencing technique patent dispute — Enzo biochem claims that they invented the technique for sequencing DNA, though the patent on it was awarded to some scientists at Caltech nearly 25 years ago. Pharmablogger presents an inside view of a series of 7,000 complaints […]


Carnival of Biotechnology

This edition of the Carnival of Biotechnology features some interesting commentary on issues ethics, how to dress for drug ads, progress in biogenerics guidance, and innovation. Trends Signals Magazine presents a Financial Snapshot For September 2006 Marketing The Pharma Marketing Blog gives us some fashion advice in Lipitor’s Jarvik: Fop or Flop? Ethics The Patent […]


Carnival of Biotechnology

This edition of the Carnival of Biotechnology features commentary on regulatory problems and progress, international development, and failed commercialization strategies. Regulatory The Washington Post has a report from the Institute of Medicine claiming that the drug review system is broken, and calling for changes. The Patent Barista’s update the road to biogenerics, profiling recent bills […]


Carnival of Biotechnology

Welcome to this week’s edition of the Carnival of Biotechnology. Some pretty good stuff this week. More Vioxx news, the human genome stops by for an update, and no love for the FDA. Finance SignalsMag provides an update on March financials: Modest Gains, Solid Quarter. Regulation The Drug Wonks take a Dumb and Dumber approach […]


Carnival of Biotechnology

This week’s edition of the Carnival of Biotechnology addresses a number of issues challenging the biotechnology industry today. Innovation About biotech proclaims Innovation is dead, long live innovation! in the wake of Proctor & Gamble’s spin of the dissolution of it’s pharma R&D efforts as a bold new innovation strategy. A Vc asks changing our […]